History of a gene patent: tracing the development and application of commercial BRCA testing.
نویسنده
چکیده
The patenting and commercialization of human genetic material raises a host of complex social, ethical, and policy issues, such as the potential for discrimination or stigmatization in access to health care services or employment, the exploitation of minority or indigenous communities in DNA prospecting, and the implications for ongoing biomedical research and access to health care services. But in order to conduct a comprehensive analysis of even one of these issues, it is crucial to first develop a detailed understanding of the particular history and context that have shaped the issue. The objective of this paper is to provide such a description of one particular case, namely the patenting by Myriad Genetics of the two genes (BRCA1 and BRCA2) associated with hereditary breast and ovarian cancer. Following a brief discussion of the aetiology of hereditary breast and ovarian cancer, the founding of Myriad Genetics and its transformation into a biopharmaceutical company is examined as part of the larger context of the international race to discover and patent the BRCA genes. The paper then focuses on Myriad’s development and control of public and commercial BRCA testing in the United States, their recent moves to enforce the patents and establish markets in Europe and Canada, and the mounting Canadian and international opposition to Myriad’s commercialization and control of BRCA testing.
منابع مشابه
analysis of contract law of commercial expectations in patent license
In this research, protection of commercial expectation has been examined. The main question is how we could identify and assess existence of commercial expectations. In response, commercial expectation are acquisition of expectable benefit in market, mass production, absence of technical failure in licensed knowledge and so on. Therefore, it is essential to response by analysis of contract law ...
متن کاملSupreme Court ruling broadens BRCA testing options.
T he day after Mother's Day, actress Angelina Jolie wrote an op-ed in the New York Times revealing her decision to undergo a double mastectomy after learning that she carries a deleterious mutation in the BRCA1 gene. Jolie and women like her who have certain germ-line BRCA1 or BRCA2 mutations are at higher risk for breast and ovarian cancers. Jolie, whose mother died from ovarian cancer, said s...
متن کاملThe patent is political: the consequences of patenting the BRCA genes in Britain.
OBJECTIVES The paper explores the attempt by an American biotechnology company, Myriad Genetics, to use its patent rights over the BRCA genes to transfer its technology of genetic testing for breast and ovarian cancer to Britain. It also investigates the responses of British scientists, health care professionals and patient advocates to this attempted technology transfer. METHODS This paper i...
متن کاملA Comparative Study on Patent Attorney in the Islamic Republic of Iran and the World Intellectual Property Organization (WIPO)
متن کامل
P-144: Egg and Embryo Donor's Application Forms in Infertility Centers; Medical, Genetic and Psychosocially Forms in Evaluating Potential Donor Candidate
Background: Nowadays, gamete and embryo donation is applied as effective process in treatment infertility problems. In order to participate in the process of donation, donors should complete an extensive questionnaire that details their personal and family medical history. Included in this questionnaire should be a detailed sexual history, substance abuse history, history of family disease, and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Health law journal
دوره 10 شماره
صفحات -
تاریخ انتشار 2002